Navigation Links
Solera Holdings, Inc. Appoints Jason Brady as General Counsel
Date:3/11/2008

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Solera Holdings, Inc. (NYSE: SLH), the leading global provider of software and services for the automobile insurance claims processing industry, today announced the appointment of Jason Brady as Senior Vice President and General Counsel, responsible for the Company's global legal organization, including corporate compliance and governance and mergers and acquisitions.

Brady has more than 12 years of relevant law experience, and in past positions has been responsible for SEC reporting and compliance, corporate transactions, corporate governance, litigation, commercial collaborations, intellectual property matters and employment matters.

He previously served as Vice President, General Counsel and Corporate Secretary at Xenogen Corporation, a publicly traded biotechnology company that was sold to Caliper Life Sciences, Inc. Prior to that, Brady held senior legal positions with Abbott Diabetes Care, TheraSense, Inc., Ensera, Inc. and AllAdvantage. At Ensera, he gained valuable insight into the software and services segment of the automobile insurance claims processing industry, working closely with Solera's founder, chairman and CEO, Tony Aquila, to build the business as a member of Ensera's senior management team. Jason started his career at the law firm of Wilson Sonsini Goodrich & Rosati in Palo Alto, California.

"I am looking forward to working with Jason Brady again as his legal counsel was instrumental at Ensera," said Aquila. "With Solera's May 2007 IPO and NYSE listing, and international business presence, the legal function remains critical to our success worldwide. Jason has a strong track record of achievement, and I intend to leverage his skills and expertise as par
'/>"/>

SOURCE Solera Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results
2. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
3. Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry
4. NightHawk Radiology Holdings, Inc. Announces Board Member Departure
5. NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
6. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
7. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
8. NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance
9. Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC
10. NightHawk Radiology Holdings, Inc. Announces Time Change for Fourth Quarter and Full-Year 2007 Earnings Conference Call
11. MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...rasylol have a higher death risk, data review find...-- A new study casts more doubt on the safety of t...ng in patients undergoing surgery. , Trasylol i... States, where it was removed from the market in 2...n researchers reviewed findings from 49 randomized...
(Date:12/2/2008)...Dec. 2 Seniors, disable...ompanies gathered today to,oppose efforts by Blue...tion,through the lame duck session of the Legisla...death for many of us in Michigan," said,RoAnne Ch...ility Rights,Coalition. "A vote for this bill is ...
(Date:12/2/2008)...o)Rare injuries accounted for 3.5 percent of high ...ding to the first study to examine rare injuries a...njuries include eye injuries, dental injuries, nec...llness, which may result in high morbidity, costly...ences. , Football was associated with the highes...
(Date:12/2/2008)... Today, advocates for t...ntry are coming together at Liz,Claiborne Inc. to...top Teen,Dating Abuse. Ann and Chris Burke, educa...dered by her abusive ex-boyfriend, are joining eff... on this national coalition that will,consist of ...
Breaking Medicine News(10 mins):Health News:Another Study Warns of Risk From Cardiac Surgery Drug 2Health News:Opposition Continues to Grow to Blues' Legislation 2Health News:Opposition Continues to Grow to Blues' Legislation 3Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 2Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 3
...the National Institutes of Health, United States, ...t -of –interests. This involves going against the ...l advice and help to a private company. Sutherland...s accused of proving the giant drug company, Pfize...
...ugs and radiation. But recent studies reveal that ...e mortality of cancer victims by 50 to 60 percent....e benefits of exercise in the prevention of hear...ittle is known about the effects of exercise on ca...
...olesterol, blood pressure and cardio-vascular prob...-based laboratory//. Pharmacists at Dr Reddy’s ha...olesterol-lowering statin, two blood-pressure medi...e world’s first ‘polypill’ is expected to control ...
... in Mars as believed earlier but ‘very liquid, ver...cient water on Mars," said Ken Edgett, a scientist...conference. "Today, we are talking about liquid wa...s right now.” The pictures taken by NASA's Mars G...
Other Medicine News:Health News:Poly-pill – A Single Drug For Multiple Complaint 2
(Date:12/1/2008)...e-USNewswire/ -- New research has found that the a...ography (CT) scanner in an emergency room can sign...o receive a potentially life-saving treatment. Res...l Center (NSMC)-Salem Hospital in Salem, Mass., wi... Radiological Society of North America (RSNA). , ...
(Date:12/1/2008)...ire/ -- TargeGen has announced that an oral,prese...r, US-based clinical,trial of TG101348 in myelopr...,the 2008 American Society of Hematology (ASH) Me...as follows:, Title: A Phase I S... JAK2-Selective Inhibitor, in Patie...
(Date:12/1/2008)...tasia Treated With ENB-0040 at Children,s Hospital...NTREAL, Dec. 1 Enobia Pharma, an e...ping novel therapeutics for serious bone disorders... its clinical program for hypophosphatasia was dos...rapy (ERT) with ENB-0040 for the treatment of this...
(Date:12/1/2008).... 1 Genaera Corporation...subjects has begun in study MSI-1436C-102 (Study 1... trodusquemine (MSI-1436) in overweight and obese ...for the treatment of type 2 diabetes and obesity w...insulin and leptin pathways through the highly sel...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release with seq 2998 1Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release with seq 2998 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release with seq 2998 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release with seq 2998 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release with seq 2998 5A reputation for innovation 4796 1A reputation for innovation 4796 2Governor Rendell Announces Resignation of Health Secretary Dr Calvin Johnson 26201 1Governor Rendell Announces Resignation of Health Secretary Dr Calvin Johnson 26201 2Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 26196 1Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 26196 2Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 26196 3Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 26196 4
...22, 2007 /PRNewswire/ -- Principal,investigators f...roliferative for Restenosis) trial, the pivotal st...luting coronary stent,presented today the clinica...investigators confirmed that the study failed to m...ed this conclusion in a,press release on Monday, M...
... FDA Approval of SEROQUEL XR--, WILMINGTON, Del., ... today announced that two analyses from a large-sc...EL XR(TM) (quetiapine,fumarate) Extended-Release T... schizophrenia in adult patients, were presented t...tric Association,(APA). These analyses from the cl...
Other Medicine Technology:Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial,Results at EuroPCR 2007 2Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial,Results at EuroPCR 2007 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
Wipe + Wick
Ophthalmic Ring
Lacrimal Cannula, Straight, Stepped DownSize: 19g x 1-1/2".
PremierEdge™ Slit Knives.
Medicine Products: